Core Insights - A Co-CEO of Amylyx Pharmaceuticals executed significant insider selling, but the sale was primarily to cover option costs and tax obligations, not discretionary [6][7] - The company has shown strong stock performance, with a 313% increase over the past year, recovering from previous losses [4][7] Transaction Summary - Joshua B Cohen sold 138,167 shares for approximately $1.9 million, following the exercise of 200,000 stock options [1][2] - Post-transaction, Cohen holds 3,379,465 shares, representing a 4.07% insider ownership [2][7] Company Overview - Amylyx Pharmaceuticals focuses on developing therapeutics for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) [5] - The company is advancing its flagship therapy, AMX0035 (RELYVRIO), which has shown effectiveness in slowing ALS progression [8] Financial Performance - The company's market capitalization is $1.57 billion, with a net income of -$149.28 million [4] - The stock price as of January 31, 2026, was $14.29, reflecting a significant recovery and growth [4] Investigations - Amylyx is currently under investigation for alleged breaches of fiduciary duties by its directors and officers, which may be a concern for investors [9]